MedTrace Logo

NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study

NCT06604884 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shield Technology™ ("Pipeline™ Vantage Device") in a post approval setting.

Conditions

  • Intracranial Aneurysm

Interventions

DEVICE

Treatment of Intracranial Aneurysms

Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™

Sponsors & Collaborators

  • Medtronic Neurovascular Clinical Affairs

    lead INDUSTRY

Principal Investigators

  • Harsh Sancheti · Medtronic

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-12
Primary Completion
2029-08-31
Completion
2033-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604884 on ClinicalTrials.gov